Logo image of KMDA

KAMADA LTD (KMDA) Stock Price, Forecast & Analysis

USA - Nasdaq - NASDAQ:KMDA - IL0010941198 - Common Stock

7.06 USD
-0.05 (-0.7%)
Last: 12/31/2025, 8:11:20 PM

KMDA Key Statistics, Chart & Performance

Key Statistics
Market Cap407.22M
Revenue(TTM)174.79M
Net Income(TTM)20.45M
Shares57.68M
Float31.45M
52 Week High9.15
52 Week Low5.54
Yearly DividendN/A
Dividend Yield2.83%
EPS(TTM)0.36
PE19.61
Fwd PE15.61
Earnings (Next)03-03 2026-03-03/bmo
IPO2005-08-01
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


KMDA short term performance overview.The bars show the price performance of KMDA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 2 -2 -4 -6 -8 -10

KMDA long term performance overview.The bars show the price performance of KMDA in the last 1, 2 and 3 years. 1 year 2 years 3 years 20 40 60

The current stock price of KMDA is 7.06 USD. In the past month the price increased by 2.02%. In the past year, price increased by 9.46%.

KAMADA LTD / KMDA Daily stock chart

KMDA Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 24.18 403.83B
AMGN AMGEN INC 14.97 176.25B
GILD GILEAD SCIENCES INC 14.99 152.28B
VRTX VERTEX PHARMACEUTICALS INC 26.12 115.03B
REGN REGENERON PHARMACEUTICALS 17.15 81.12B
ALNY ALNYLAM PHARMACEUTICALS INC 779.71 52.53B
INSM INSMED INC N/A 37.12B
NTRA NATERA INC N/A 31.62B
BIIB BIOGEN INC 10.51 25.82B
UTHR UNITED THERAPEUTICS CORP 18.46 20.98B
INCY INCYTE CORP 15.38 19.39B
EXAS EXACT SCIENCES CORP N/A 19.27B

About KMDA

Company Profile

KMDA logo image Kamada Ltd. is a biopharmaceutical company, which focuses on specialty plasma-derived therapeutic. The firm uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.

Company Info

KAMADA LTD

2 Holtzman St., Science Park

Rehovot 7670402 IL

CEO: Amir London

Employees: 374

KMDA Company Website

KMDA Investor Relations

Phone: 97289406472

KAMADA LTD / KMDA FAQ

Can you describe the business of KAMADA LTD?

Kamada Ltd. is a biopharmaceutical company, which focuses on specialty plasma-derived therapeutic. The firm uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.


What is the current price of KMDA stock?

The current stock price of KMDA is 7.06 USD. The price decreased by -0.7% in the last trading session.


What is the dividend status of KAMADA LTD?

KAMADA LTD (KMDA) has a dividend yield of 2.83%. The yearly dividend amount is currently 0.


How is the ChartMill rating for KAMADA LTD?

KMDA has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 6 out of 10.


Which stock exchange lists KMDA stock?

KMDA stock is listed on the Nasdaq exchange.


Can you provide the market cap for KAMADA LTD?

KAMADA LTD (KMDA) has a market capitalization of 407.22M USD. This makes KMDA a Small Cap stock.


What is the ownership structure of KAMADA LTD (KMDA)?

You can find the ownership structure of KAMADA LTD (KMDA) on the Ownership tab.


KMDA Technical Analysis

ChartMill assigns a technical rating of 5 / 10 to KMDA. When comparing the yearly performance of all stocks, KMDA turns out to be only a medium performer in the overall market: it outperformed 65.87% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

KMDA Fundamental Analysis

ChartMill assigns a fundamental rating of 6 / 10 to KMDA. While KMDA belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

KMDA Financial Highlights

Over the last trailing twelve months KMDA reported a non-GAAP Earnings per Share(EPS) of 0.36. The EPS increased by 28.57% compared to the year before.


Industry RankSector Rank
PM (TTM) 11.7%
ROA 5.42%
ROE 7.72%
Debt/Equity 0.04
Chartmill High Growth Momentum
EPS Q2Q%28.57%
Sales Q2Q%12.63%
EPS 1Y (TTM)28.57%
Revenue 1Y (TTM)10.36%

KMDA Forecast & Estimates

9 analysts have analysed KMDA and the average price target is 13.26 USD. This implies a price increase of 87.82% is expected in the next year compared to the current price of 7.06.

For the next year, analysts expect an EPS growth of 44.17% and a revenue growth 12.37% for KMDA


Analysts
Analysts84.44
Price Target13.26 (87.82%)
EPS Next Y44.17%
Revenue Next Year12.37%

KMDA Ownership

Ownership
Inst Owners11.39%
Ins Owners2.34%
Short Float %0.24%
Short Ratio0.95